Welcome to the Oncology Brothers podcast! In this episode, we dived into the evolving treatment algorithms for bladder cancer following the latest data presented at GU ASCO 2026.

Join us as we explore:

  • The role of immunotherapy in non-muscle invasive bladder cancer, highlighting the recent positive trials: CREST with Sasanlimab and POTOMAC with Durvalumab.
  • Insights on the current standard of care and the implications of combining BCG with immunotherapy.
  • The shift in treatment strategies for muscle-invasive bladder cancer, including the new standard of care with the EV-Pembro combination and its impact on pathologic complete response rates.
  • The challenges and considerations in managing side effects associated with new therapies, as well as the importance of patient selection and coordination between urologists and medical oncologists.
  • The emerging role of ctDNA in guiding treatment decisions and the ongoing discussions around the sequencing of therapies in refractory settings.

Hope you enjoy this informative discussion that aims to keep you up to date in the world of cancer treatment, here focusing on bladder cancer.

Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

  • ⁠X/Twitter: https://twitter.com/oncbrothers
  • Instagram: https://www.instagram.com/oncbrothers
  • Website: https://oncbrothers.com/

Subscribe to our channel for more episodes and discussions on the latest in oncology!

BladderCancer, #NMIBC, #MIBC, #Immunotherapy, #GU26, #OncologyBrothers

See All 279 Episodes of "Oncology Brothers"